BIO Share Price

Open 28.00 Change Price %
High 28.00 1 Day 0.28 1.02
Low 27.79 1 Week 0.09 0.32
Close 27.79 1 Month -0.51 -1.80
Volume 72 1 Year 11.09 66.41
52 Week High 28.60
52 Week Low 15.66
BIO Important Levels
Resistance 2 27.98
Resistance 1 27.90
Pivot 27.86
Support 1 27.68
Support 2 27.60
ETR Germany Most Active Stocks
DBK 15.53 -6.45%
DBK 15.53 -6.45%
DTE 15.65 0.84%
DTE 15.65 0.84%
DTE 15.65 0.84%
DTE 15.65 0.84%
DTE 15.65 0.84%
CBK 11.13 0.09%
CBK 11.13 0.09%
EOAN 8.43 0.60%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
5M71 39.00 13.70%
N4G 5.80 12.62%
WSU 69.30 7.61%
BEO 3.38 6.96%
A6T 4.24 6.53%
ESY 7.60 6.15%
E8X 0.35 6.06%
SRT 80.35 5.88%
SRT 80.35 5.88%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
NK2A 0.05 -16.67%
GTQ1 14.63 -15.77%
ZEG 49.23 -15.72%
VSC 4.84 -12.00%
VSC 4.84 -12.00%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 4
As on 27th Jul 2017 BIO Share Price closed @ 27.79 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 20.92 & Buy for SHORT-TERM with Stoploss of 27.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for July
1st Target up-side 28.54
2nd Target up-side 29.01
3rd Target up-side 29.48
1st Target down-side 27.2
2nd Target down-side 26.73
3rd Target down-side 26.26
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.